The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Oncology; Bayer; Elekta; Ferring; Genesis Healthcare Partners; Janssen
Research Funding - Accuray; Elekta; MSD
Efficacy and toxicity according to hormone therapy used in the CHHiP trial.
 
Alison Tree
No Relationships to Disclose
 
Clare Griffin
Research Funding - Accuray (Inst)
 
Emma Hall
Research Funding - Accuray (Inst); Alliance Pharma (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst)
 
David P. Dearnaley
Honoraria - Janssen; Sandoz; Takeda
Consulting or Advisory Role - Cadence Research and Consulting; FirstWord; Janssen; Janssen Research & Development; Sandoz; Takeda
Speakers' Bureau - Janssen; Janssen-Cilag
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst); Patent issued EP1933709B1 (location and stabilisation device)
Expert Testimony - Vitality Life
Travel, Accommodations, Expenses - Janssen; Takeda